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Abstract
Bisphosphonates is a group of inorganic pyrophosphates analogues that suppress bone resorption by inducing 
osteoclast inactivation, being frequently used for management of diseases affecting bone metabolism, bone me-
tastases and bone tumors. However, since 2003 many cases describing the presence of necrotic bone exposures 
in the jaws have been described in patients receiving these drugs, what represent a signiﬁcant complication of 
bisphosphonates treatment. The overall incidence of bisphosphonate-related osteonecrosis of the jaws is low, rang-
ing from 0.7% to 12%, mainly observed in those patients receiving intravenously treatment. Osteonecrosis of the 
jaws associated to oral bisphosphonate, particularly alendronate, has also been reported by a number of authors. 
Considering that alendronate is one of the most used drugs worldwide, specially for treatment of osteoporosis, a 
better understanding of osteonecrosis of the jaws related to its use and how to manage these patients is extremely 
important. Therefore, in the current manuscript the authors aim to review the most important topics related to this 
pathological presentation.
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Introduction
Bisphosphonates (BPs) is a group of analogues of in-
organic pyrophosphates that suppress bone resorption 
by inhibiting farnesyl pyrophosphate synthase enzyme 
in osteoclasts, thus interfering with geranylgeranylation 
(attachment of the lipid to regulatory proteins), ﬁnally 
inducing osteoclast inactivation and inhibiting its func-
tion and maturation. BPs have been currently considered 
the ﬁrst-choice therapy in the management of diseases 
affecting bone metabolism (osteoporosis and Paget’s 
disease) and bone metastases (1-4). BPs differ one from 
another in substitution of the active side chains on their 
phosphorous-carbon-phosphorous structural backbone. 
The ﬁrst generation of BPs (etidronate, clodronate) pos-
sesses alkyl or halide side groups, whereas the second 
generation (pamidronate) contains an amino-terminal 
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group. In 2002 it was authorized the clinical use of the 
zoledronic acid (zoledronate) that represented the third 
generation of BPs. Zoledronate contains an imidazole 
ring group in its side chain and is about 100 times more 
potent than pamidronate and even stronger than the ﬁrst 
generation of BPs (2,5-7).
Although BPs are efﬁcient drugs, since 2003 some re-
ports have presented necrotic bone exposures in patients 
receiving these drugs (Fig. 1), representing a signiﬁcant 
Fig. 1. A) Clinical aspect of AONJ presenting an uncommon and extensive osseous involvement well illustrate in B) panoramic radio-
graph and C) computed tomography exams.
complication of BP treatment. The American Associa-
tion of Oral and Maxillofacial Surgeons (AAOMS) de-
ﬁned the bisphosphonate-related osteonecrosis of the 
jaws (BRONJ) as the presence of exposed necrotic bone 
in the maxillofacial region that does not heal within 8 
weeks after clinical identiﬁcation, in a patient currently 
or previously treated with BPs, who has never under-
gone radiotherapy to the jaws (8). The overall incidence 
of BRONJ is low, ranging from 0.7% to 12% in those 
patients submitted to intravenously treatment (8). 
These drugs can also be administered orally and alen-
dronate represents by far the oral nitrogen-containing 
BP most commonly used to treat osteoporosis, what is 
well illustrated by the 27 million prescriptions in Unit-
ed States in 2008 (75% for alendronate). With the oral 
administration, even after only a few weeks of intake, 
adequate levels of bone resorption inhibition can be ob-
served (1,2,9). However, occurrence of osteonecrosis of 
the jaws related to alendronate has also been reported 
by several authors (1,2,6,8). 
The aim of the current article is to review key issues 
concerning alendronate-associated osteonecrosis of the 
jaws (AONJ), discussing its potential risk factors, treat-
ment options and the awareness of the health care work-
ers and of the patients that are receiving this therapy.
Material and Methods
-What is the potential risk for alendronate-associated 
bone necrosis?
Oral BPs are potent osteoclast inhibitors, but they are 
not highly efﬁcacious in the treatment of malignant os-
teolytic disease and, therefore, are mostly indicated for 
the treatment of osteoporosis (10). It is estimated that 
over 190 million prescriptions for oral BP have been 
dispensed worldwide and alendronate is by far the most 
common of the oral BPs prescribed (11). 
AONJ has been reported by a number of authors and 
given the increasing number of persons taking alen-
dronate, a better understanding of the epidemiology of 
osteonecrosis of the jaws and oral BP therapy is critical 
(12,13). According to the manufacturer of Fosamax® 
(commercial name of alendronate) (Merck, Whitehouse 
Station, NJ, USA), an incidence rate of 0.7 to 1 cases 
of AONJ per 100,000 patients taking the drug or 170 
cases worldwide, was suggested for 2006. The current 
estimate prevalence has ranged from 0.001% to 0.01% 
among oral bisphosphonate-treated populations, what is 
signiﬁcantly inferior than the incidence observed in pa-
tients undergoing intravenous therapy (3,4,12-15). How-
ever, Sedghizadeh et al. (14) found an incidence as high 
as 4% of AONJ by evaluating 208 osteoporotic patients, 
indicating that this incidence could be higher than the 
usually reported. 
Female patients in the sixth to seventh decade of life have 
been reported to be more affected by AONJ than males, 
what may be consequence of the signiﬁcantly higher inci-
dence of osteoporosis in this group of individuals (11-14). 
Moreover, patients receiving alendronate due to other 
pathological entities, such as Paget’s disease, osteogen-
esis imperfecta and rheumatoid arthritis, have also been 
reported to develop AONJ (16-19).
Hence, although rarely described if compared to os-
teonecrosis of the jaws associated to the use of intravenous 
BPs, AONJ must be considered a potential side-effect of 
patients under alendronate therapy, most commonly seen 
in elderly female patients affected by osteoporosis.
-What are the predisposing factors?
Despite the nature of BRONJ has not been well deter-
mined and the impossibility of establishing the real risk 
for developing BRONJ for a certain patient, several risk 
factors have been connected. Hence, the role of comor-
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bidities in the pathogenesis and prognosis of BRONJ 
has been suggested and the presence of diseases that 
compromise blood supply, cellular metabolism, oxy-
genation, and immune response such as diabetes, hy-
pertension, hypercholesterolemia and obesity, as well 
as the chronic use of corticosteroids, methotrexate and 
thalidomide and smoking habit may have a synergistic 
effect in the initiation and outcome of oral and intrave-
nous BRONJ (9,14,20). 
In addition, it is well known that not only the potency 
of BPs, but also the period of taking and route of ad-
ministration are important features for determining the 
risks for osteonecrosis onset. Speciﬁcally regarding oral 
BPs it has been shown that the risk of developing ONJ 
is closely related to the therapy duration and it seems 
to be higher after 3 years of treatment  (14,21). Lo et al. 
(12) observed that the prevalence of osteonecrosis was 
greater among patients receiving oral BPs with more 
than 4 years of exposure compared with those with less 
than 4 years of exposure. Similarly, Marx et al. (22) re-
ported an exponential relationship between the size of 
bone exposure and the duration of oral BP use, observ-
ing that all patients who developed osteonecrosis took 
an oral BP for more than 3 years.
Local variables could also raise the incidence of BRONJ 
(2,23). Tooth extraction is the event most commonly pre-
ceding BRONJ in clinical series and given the available 
evidences, current guidelines discourage tooth extraction 
in patients receiving both oral and IV BPs (8,14,21,24,25). 
Manfredi et al. (20) observed a history of oral surgery at 
the site affected by osteonecrosis in 58.3% of their pa-
tients receiving alendronate therapy and the majority of 
them reported tooth extraction months before AONJ ap-
pearance. Different authors also identiﬁed local trauma 
resulting from ill-ﬁtted dentures as the initiating event 
in a percentage of their AONJ patients, highlighting 
this necessity of adequate prosthodontic follow-up for 
these group of individuals (18,26,27). Moreover, bony 
outgrowths such as mandibular and palatine tori can be 
easily traumatized and should be recognized as potential 
sites at risk for AONJ (21,22,28-30).
Regarding dental implants, the AAOMS divides pa-
tients taking oral-BPs into two risk groups. 1) those 
who have been taking oral-BPs for < 3 years and are 
directly eligible for implant treatment and 2) those who 
have been taking oral-BPs for > 3years or for < 3 years 
but simultaneously taking corticosteroids. For this sec-
ond group a BP drug interruption 3 months before and 3 
months after implant therapy was recommended if sys-
temic health of the patient allows (21).
In terms of implant failure, Jeffcoat (31) reported 100% 
success rate for 102 implants with no clinical evidence 
of infection, pain or bone necrosis in patients receiving 
alendronate for a mean duration of 3 years. Marx et al. 
(22) observed that only 6.7% of their sample receiving 
oral BPs developed osteonecrosis as a result of implant 
placement. Similarly, Martin et al.(32) observed that 
only 2.7% of their patients receiving oral BPs (589 pa-
tients) exhibited implants failures, whereas Grant et al. 
(33) by evaluating 115 patients who had received oral 
BP therapy and dental implants, observed no evidence 
of BRONJ in any of the patients evaluated. Fugazzotto 
et al. (34) retrospectively evaluating 61 osteoporotic fe-
male patients under oral BP therapy observed that only 
one patient demonstrated a small tissue dehiscence at 
the 1-week postoperative examination, stating that oral 
BPs use for a mean period of 3.3 years would not be a 
contributing factor to the development of osteonecrosis 
following implant placement. Hence, taken these results 
together, it can be assumed that implant success for pa-
tients receiving oral BP therapy is similar to those not 
receiving oral BP therapy.  
With the purpose of identifying which patients had a 
greater risk of BRONJ, it has been proposed the useful-
ness of determining serum CTX (telomere C-terminal 
of collagen 1), a biologic index to measure bone remod-
eling and bone resorption, pointing out that those pa-
tients who had taken oral BPs for more than 3 years and 
who had CTX below 150 pg/ml would be at greater risk 
of developing BRONJ during dental surgery (22,35). 
Kwon et al. (36) correlated the staging of osteonecrosis 
with serum CTX in 18 osteoporotic patients receiving 
oral BPs treatment, the authors found a signiﬁcant cor-
relation between the disease severity and the risk as-
sessment using serum CTX. However, Fleisher et al. 
(37) evaluating 26 patients receiving IV or oral BPs with 
CTX levels < 150 pg/ml that underwent teeth extrac-
tions or surgical procedures for treatment of BRONJ, 
observed that all individuals healed successfully after 
surgical managements, emphasizing that healing for 
these patients can occur even in the presence of low 
serum CTX levels and that other clinical parameters, 
such as periodontal changes, could be more predictable 
of BRONJ development.
In summary, although some reports indicate that AONJ of 
the jaws can develop spontaneously without a clear cause 
(5,19,22), numerous risk factors are currently effectively 
associated with an increased AONJ rates especially the 
duration of therapy and the history of tooth extraction. 
However, in contrast to the contraindicative advertise-
ments of all guidelines concerning implant placement 
in patients receiving IV-BPs, patients treated with alen-
dronate do not seem to present increased rates of implant 
failures if compared to individuals who have never un-
dergone alendronate therapy. Moreover, although further 
studies are necessary to conﬁrm the clinical efﬁcacy of 
CTX serum levels in predicting clinical behavior and risk 
of developing osteonecrosis in patients taking BPs, this 
seems to be a useful laboratorial parameter for managing 
patients under oral BPs treatment. 
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-How to treat bone necrosis? 
The management of patients with BRONJ remains ex-
tremely difﬁcult, with numerous recommendations 
being proposed and controversially discussed, but no 
consensus on a standard of care has been reached. In 
addition, there is no agreement on a surgical versus 
nonsurgical approach to therapy, especially because 
most of the relevant literature reports heterogeneous 
case studies or retrospective analyses that are difﬁcult 
to be compared (23,28).
Surgical debridement with the goal of covering the ex-
posed bone has not been completely effective. The un-
certain outcomes of surgical treatment probably stem 
from the inability of surgically remove the necrotic 
bone to a safe margin with viable bleeding bone. In ad-
dition, surgery may create a bone wound that will not 
heal because of the BP therapy itself, originating a sec-
ondary osteonecrosis from the surgical margins (10,38). 
Therefore, contradictory results have been described by 
different authors regarding the efﬁcacy of surgical ap-
proaches in BRONJ treatment.
Speciﬁcally concerning oral BPs, it is known that they 
present an inferior potency than their intravenous coun-
terpart, since orally administered BPs allow less than 
1% of drug absorption. It has been observed that oral 
bisphosphonate-related ONJ is generally less severe and 
it is more responsive to a more conservative treatment 
than IV bisphosphonate-induced osteonecrosis. In ad-
dition, it seems that ONJ oral bisphosphonate-related 
correlates well to the serum CTX levels, therefore, be-
coming more predictable (12,22,29). Hence, it has been 
suggested that for patients who present with exposed 
bone due to an oral BP, the drug should be discontinued 
by the prescribing physician if possible and a CTX test 
be required. If the exposed bone is painless, a conserva-
tive approach with 0.12% chlorhexidine is initially suf-
ﬁcient. However, if the patient reports pain or if clini-
cal evidence of infection is present, antibiotic therapy 
should be provided in addition to the 0.12% chlorhexi-
dine. Surgery with local debridement should be re-
served for cases refractory to these initial conservative 
approaches (21,22).
In summary, although innumerous guidelines have been 
suggested by different groups in the last years regarding 
BRONJ treatment, no consensus has been obtained. For-
tunately, it has been noted that AONJ may represent a sig-
niﬁcantly less aggressive and more predictable condition if 
compared to IV BPs-ONJ, arguing for a more conservative 
management with improved oral hygiene and local and 
systemic antibiotics, reserving surgical approaches for re-
fractory situations. Figures 2,3 illustrate two patients who 
developed AONJ and had complete resolution.    
-Interrupt drug use may prevent bone necrosis?
Additionally to the absence of a well established thera-
peutic approach in cases of BRONJ, the uncertainties 
Fig. 2. A) AONJ on the palate associated with trauma caused by 
prosthesis. B) The lesion exhibited complete resolution following 
conservative treatment. 
Fig. 3. A, B) Clinical and radiographic aspects of AONJ after tooth 
extraction. C, D) Complete resolution after conservative removal of 
the necrotic bone. 
concerning the influence of BP treatment discontinua-
tion in the outcomes of the patients undergoing BRONJ 
treatment, remains highly obscure. It is known that 
nitrogen-containing BPs are not metabolized and that 
50% of it are secreted in the urine unchanged and the 
rest bind to bone, being slowly released into the circula-
tion. As a consequence, their half-life in the bone could 
be as long as 10 years. Therefore, it is thought that the 
actions of BPs may continue for all this time even after 
they have been discontinued (3,14,23,28,38). 
When evaluating 25 osteoporotic patients treated with 
oral BP, Manfredi et al. (20) did not observe differ-
ences in the healing process between individuals who 
suspended treatment and those who did not. However, 
other studies have shown that the cessation of oral or 
IV BP treatment before dental surgical approaches 
would signiﬁcantly favor an improvement in patients’ 
outcome and reduce the risk for BRONJ, probably be-
cause the newly formed bone would be unable to absorb 
BPs (23). Marx et al. (22) observed that 6-month drug 
holiday showed a direct and signiﬁcant improvement in 
the CTX values in patients receiving oral BP therapy, 
demonstrating a clinical bone recovery and important 
response to a drug discontinuation.
Thus, recent reports are in favor of giving to the patient 
a drug holiday before surgical procedures is performed 
especially for individuals receiving oral BPs. However, 
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1 AONJ presents a signiﬁcantly inferior incidence than IV BP- related ONJ and is commonly found in female patients 
undergoing osteoporosis therapy.
2 Tooth extraction and duration of alendronate therapy seems to be the most important factors predisposing AONJ 
onset.
3 Patients treated with alendronate do not seem to present increased rates of implant failures if compared to individuals 
who have never undergone alendronate therapy. 
4 Serum CTX level and drug discontinuation are believed to correlate better with patients receiving alendronate than 
those under IV management.
5 A more conservative initial management with local and/or systemic antibiotic therapy is recommended for patients 
affected by AONJ, whereas surgery must be reserved for refractory situations.
6 Patients receiving oral and IV BP therapy and a great proportion of dental professionals are not adequately aware of 
possible complications related to this treatment modality.
Table 1. Summary of the most important topics related to AONJ.
AONJ: Alendronate-associated osteonecrosis of the jaws; IV: Intravenous; BP: Bisphosphonates; ONJ: Osteonecrosisof the jaws; 
CTX: Telomere C-terminal of Collagen 1.
the decision to suspend BP treatment should be taken 
by the prescribing physician rather than the dentist, and 
before considering the discontinuation of the oral BP 
therapy for a patient with osteoporosis, the very limited 
risk of AONJ must be weighed against the positive ef-
fects on health of oral BP use (9,20).
-How aware are the patients and health care workers 
about the side-effects?
The increasing frequency of new cases being described in 
the literature and the appearance of consensus guidelines 
on BRONJ prompted some researchers to determine the 
level of knowledge of patients, dentists and dental stu-
dents concerning BPs and osteonecrosis. Lópes-Jornet et 
al. (35), Migliorati et al. (15) and Bauer et al. (3) observed 
that in all groups only a minority knew adequate infor-
mation concerning the use of BPs, suggesting that greater 
educational efforts should be made to promote knowledge 
of this pathology at both undergraduate and postgraduate 
levels, and that the majority of the patients receiving oral 
or IV BPs are not adequately informed about possible ad-
verse effects of their BP therapy. Table 1 shows the most 
important to-pics related to AONJ. 
Conclusions
Patients under oral bisphosphonate use are of lower risk 
for bone necrosis of jaw, this side-effect is generally less 
severe and it is more responsive to treatment compar-
ing to ONJ in patients taking intravenous formulations. 
Although relatively uncommon, dental extraction is the 
most common risk factor for ONJ. Drug discontinua-
tion and serum CTX levels may be useful to prevent 
ONJ. Finally, physicians, dentist and patients should be 
aware of this possible side-effect of oral BP therapy, 
since the knowledge and dental preventive measures 
can signiﬁcantly reduce the risk of developing this con-
dition. 
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